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S U M M A R Y
Background: Endothelial infection has an important role in the pathogenesis of Crimean-Congo
hemorrhagic fever (CCHF). In this study, we investigated the causes of vascular endothelial damage
in patients with CCHF.
Methods: This prospective case-controlled study was carried out at Ankara Numune Education and
Research Hospital between April and September 2007. Seventy-ﬁve patients with a laboratory-conﬁrmed
diagnosis of CCHF and 88 healthy controls were enrolled in the study. Serum levels of soluble cell
adhesion molecules (sICAM-1, sVCAM-1, sE-selectin, sP-selectin, sL-selectin), vascular endothelial
growth factor (VEGF), and macrophage migration inhibitory factor (MIF) were investigated in these
patients by quantitative sandwich ELISA technique.
Results: In the patient group, serum levels of sVCAM-1, sL-selectin andMIFwere signiﬁcantly higher than
in the control group; serum levels of sICAM-1, sP-selectin, sE-selectin, and VEGF were signiﬁcantly lower
than in the control group. Serum levels of sVCAM-1 and sICAM-1were signiﬁcantly higher in severe cases
than in non-severe cases, whereas the serum level of VEGF was signiﬁcantly lower. sVCAM-1 was
signiﬁcantly higher in non-survivors than in survivors, while serum VEGFwas signiﬁcantly lower in non-
survivors. The optimumcut-offs of sVCAM-1 and VEGF for the prediction ofmortalitywere 205 ng/ml and
125 ng/ml, respectively. At these cut-offs, sVCAM-1 and VEGF had a sensitivity of 100% and speciﬁcity of
42.5% and 54.5%, respectively, in identifying CCHF patients who would die from the disease. The positive
predictive values were 19% and 23%, respectively; negative predictive values were 100% for both.
Conclusion: Endothelial activation can affect the course of CCHF, and vascular endothelial damage is
probably indirect. Further studies are needed for general conclusions to be drawn.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne
disease caused by a Nairovirus of the family of Bunyaviridae.1 It
is a potentially fatal disease and is endemic in Africa, the Middle
East, Central Asia, and Eastern Europe, with a reported mortality
rate of 3–30%.2–4 The clinical features show a common dramatic
progression, characterized by hemorrhage, myalgia, nausea,
headache, and fever.4,5
The pathogenesis of CCHF is not well described. Endothelial
damage has an important role in the pathogenesis of CCHF. The
endothelium can be targeted indirectly by viral factors or virus-
mediated soluble factors and/or directly by viral replication.6 In
this study, we investigated the causes of vascular endothelial
damage by detection of serum levels of soluble cell adhesion* Corresponding author. Tel.: +90 312 5084840; fax: +90 312 3126876.
E-mail address: hurrembodur@gmail.com (H. Bodur).
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doi:10.1016/j.ijid.2010.02.2240molecules, vascular endothelial growth factor (VEGF), and macro-
phage migration inhibitory factor (MIF).
2. Patients and methods
This prospective case-controlled study was carried out at
Ankara Numune Education and Research Hospital between April
and September 2007. Seventy-ﬁve patients with a laboratory-
conﬁrmed diagnosis of CCHF were enrolled in the study. Serum
levels of soluble cell adhesion molecules (soluble intercellular
adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion
molecule-1 (sVCAM-1), sE-selectin, sP-selectin, sL-selectin), VEGF,
andMIF were investigated in these patients. The diagnosis of CCHF
was conﬁrmed by positive qualitative PCR test and/or positive IgM
antibody by ELISA. At admission to hospital, peripheral blood
samples were collected from the patients with signs and
symptoms compatible with CCHF for PCR and ELISA testing.
Patients with a conﬁrmed diagnosis of CCHF were included in the
study.ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Serum levels of soluble adhesion molecules, VEGF, and MIF in patients and in the
control group
Tests Patients
(n=75)
Control group
(n=88)
p-Value
sVCAM-1 (ng/ml) 192.2
(22.6–246)
30.2 (16.4–62.1) <0.001
Log sICAM-1 (ng/ml) 0.510.33 0.840.29 <0.001
Log sE-selectin (ng/ml) 0.410.31 0.830.44 <0.001
Log sP-selectin (ng/ml) 1.440.41 1.960.37 <0.001
sL-selectin (ng/ml) 36.4610.13 178.66 <0.001
VEGF (ng/ml) 122.8
(5.2–1301.1)
414.5
(35.7–1513.2)
<0.001
MIF (ng/ml) 7.093.22 4.533.25 <0.001
sVCAM, soluble vascular cell adhesion molecule; sICAM, soluble intercellular
adhesion molecule; VEGF, vascular endothelial growth factor; MIF, macrophage
migration inhibitory factor.
Data are given as mean standard deviation or median (minimum–maximum).
Table 2
Serum levels of soluble adhesion molecules, VEGF, and MIF in severe and non-
severe cases
Tests Severe cases
(n=23)
Non-severe
cases (n=52)
p-Value
sVCAM-1 (ng/ml) 213.9
(155.4–236)
205.9 (22.–246) 0.002
Log sICAM-1 (ng/ml) 0.65 0.38 0.460.30 0.02
Log sE-selectin (ng/ml) 0.39 0.33 0.420.29 0.751
sP-selectin (ng/ml) 35.5332.91 41.1632.51 0.492
sL-selectin (ng/ml) 35.2010.9 37.029.83 0.474
VEGF (ng/ml) 8.8 (5.2–231.1) 156.6
(5.2–1301.1)
<0.001
MIF (ng/ml) 7.532.87 6.903.37 0.438
sVCAM, soluble vascular cell adhesion molecule; sICAM, soluble intercellular
adhesion molecule; VEGF, vascular endothelial growth factor; MIF, macrophage
migration inhibitory factor.
Data are given as mean standard deviation or median (minimum–maximum).
Table 3
Serum levels of soluble adhesion molecules, VEGF, and MIF in survivors and non-
survivors
Tests Survivors
(n=66)
Non-survivors
(n=9)
p-Value
sVCAM-1 (ng/ml) 209.1
(22.6–246)
218.5
(205.3–236)
0.018
Log sICAM-1 (ng/ml) 0.490.33 0.67 0.37 0.153
Log sE-selectin (ng/ml) 0.390.30 0.48 0.32 0.444
sP-selectin (ng/ml) 37.7930.92 51.4842.67 0.238
sL-selectin (ng/ml) 36.969.57 32.7513.71 0.245
VEGF (ng/ml) 138.1
(5.2–1301.1)
5.2 (5.2–124.9) 0.004
MIF (ng/ml) 6.983.25 7.902.96 0.428
sVCAM, soluble vascular cell adhesion molecule; sICAM, soluble intercellular
adhesion molecule; VEGF, vascular endothelial growth factor; MIF, macrophage
migration inhibitory factor.
Data are given as mean standard deviation or median (minimum–maximum).
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was used to detect CCHF viral RNA.7 The presence of CCHF-speciﬁc
serum IgM antibodies was determined by in-house ELISA method.
The antigens used in ELISA testswere obtained from the Centers for
Disease Control and Prevention (CDC, Atlanta, GA, USA).
The clinical course and laboratory data of the patients were
recorded prospectively on individual forms. Eighty-eight healthy
blood donors were enrolled in the study as controls. Local medical
ethics committee approval for the study was obtained. All patients
and control group members included in the study gave informed
consent.
The quantitative sandwich ELISA technique was used for the
determination of serum sICAM-1 (Invitrogen, Carlsbad, CA, USA),
sVCAM-1 (Invitrogen), sE-selectin (Invitrogen), sP-selectin (Invi-
trogen), sL-selectin (Invitrogen), VEGF (Invitrogen), and MIF (R&D
Systems, Minneapolis, MN, USA) levels. Tests were performed
according to the manufacturer’s recommendations. The results
were reported in ng/ml.
In this study, serum levels of soluble cell adhesion molecules,
VEGF, and MIF were compared statistically between the patient
and control groups, between the severe and the non-severe cases,
and between non-survivors and survivors. Previously reported
disease-severity criteria were used to deﬁne the severe cases.8
Patients with at least one of the following were considered severe
cases: somnolence, melena, activated partial thromboplastin time
(APTT) 60 s, and thrombocyte count 20  109/l.
Statistical analyses were performed using SPSS 15.0 statistical
package (SPSS Inc., Chicago, IL, USA). The Kolmogorov–Smirnov
test was used to check the normality of distribution. Base 10
logarithmic transformations were performed for variables that
failed normality tests. For continuous variables, groups were
compared with the Student’s t-test. For variables that were not
normally distributed, comparisons were made with the Mann–
Whitney U-test. Sensitivity, speciﬁcity, and predictive values of
sVCAM-1 and VEGF for the prediction of mortality were estimated
at various cut-offs. A receiver operating characteristic curve was
constructed, and the area under the curve was estimated with a
95% conﬁdence interval (95% CI).
3. Results
Seventy-ﬁve conﬁrmed CCHF cases and 88 healthy controls
were included in the study. Of the 75 patients, 60 (80%) had
CCHF viral RNA detected by PCR and 65 (86.7%) had CCHF-
speciﬁc IgM antibodies detected by ELISA. Nine patients with
CCHF (12%) died; 23 (30.7%) met the criteria for severe disease.
The mean age of the patients was 41.91  17.57 (range 15–75)
years, and 40 (53.3%) were male. The mean duration of symptoms
was 5.1  1.77 (range 1–10) days. Thirty patients (40%) had clinical
manifestations of bleeding, including epistaxis (25.3%), gingival
hemorrhage (18.7%), hematemesis (14.7%), melena (8%), vaginal
bleeding (8%), hematuria (5.3%), and hemoptysis (4%). Laboratory
test results revealed a mean thrombocyte count of 62  44 (range
4–172)  109/l, mean leukocyte count of 2.813  2.133 (range 0.7–
16.5)  109/l, and mean APTT level of 41  36 (range 24–98) s. In
the control group, the mean age was 36.18  9.97 (range 16–60)
years and 64 (72.7%) were male.
Serum levels of sVCAM-1, sL-selectin, and MIF were signiﬁ-
cantly higher in the patients than in the controls, but serum levels
of sICAM-1, sP-selectin, sE-selectin, and VEGF were signiﬁcantly
lower than in the control group (Table 1). In severe cases, serum
levels of sVCAM-1 and sICAM-1 were signiﬁcantly higher than in
the non-severe cases, whereas serum VEGF levels were signiﬁ-
cantly lower than in the non-severe cases (Table 2). A relationship
was detected between mortality and serum levels of sVCAM-1
and VEGF. While sVCAM-1 was signiﬁcantly higher in thenon-survivors than the survivors, serum VEGF was signiﬁcantly
lower in the fatal cases (Table 3).
The optimum cut-off of sVCAM-1 for the prediction of
mortality, which was determined using a receiver operating
characteristic (ROC) curve, was 205 ng/ml. At this cut-off, sVCAM-1
had a sensitivity of 100% and speciﬁcity of 42.5% in identifying
CCHF patients who died from the disease (Figure 1). The positive
and negative predictive values were 19% and 100%, respectively.
The optimum cut-off of VEGF for the prediction of mortality,
determined using a ROC curve, was 125 ng/ml. At this cut-off, VEGF
had sensitivity of 100% and speciﬁcity of 54.5% in identifying CCHF
patients who died from the disease (Figure 2). The positive and
negative predictive values were 23% and 100%, respectively.
Figure 1. Receiver operating characteristic (ROC) curve for sVCAM-1. Area under
the ROC curve = 0.745, SE = 0.099 (95% CI 0.631–0.839).
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The pathogenesis of CCHF is not well described. There are
limited data in the literature. In one study, reactive hemophago-
cytosis was detected in half of the patients, and it was suggested
that hemophagocytosis might have a role in the pancytopenia that
occurs in CCHF infection.9 It has been demonstrated that the levels
of interleukin-1, interleukin-6, and tumor necrosis factor-alpha are
higher among those patients who die than those who survive.10,11
High serum neopterin levels and increased viral load have been
associatedwithmortality.12,13 In one study, CD3+CD8+ T cellswere
found to be higher in fatal cases, and it was concluded that factors
other than cytotoxic immune activation might inﬂuence the
outcome of the disease.14 CCHF is one of the newest additions to
the list of interferon-sensitive viruses. MxA signiﬁcantly con-
tributes to the antiviral activity of interferon against CCHF virus.Figure 2. Receiver operating characteristic (ROC) curve for VEGF. Area under the
ROC curve = 0.795, SE = 0.065 (95% CI 0.687–0.880).Recently it was demonstrated that several interferon-stimulated
genes most probably act in concert to combat the infection.15
Endothelial damage has an important role in the pathogenesis
of CCHF. It contributes to hemostatic failure by stimulating platelet
aggregation and degranulation, with consequent activation of the
intrinsic coagulation cascade. The endothelium can be targeted
indirectly by viral factors or virus-mediated host-derived soluble
factors that cause endothelial activation and dysfunction.6
Adhesion molecules are involved in leukocyte rolling, ﬁrm
adhesion, and transmigration. Among the adhesion molecules,
some participate in endothelial cell activation. ICAM-1 is
constitutively expressed on the vascular endothelium. VCAM-1
is expressed on a variety of cells, including activated vascular
endothelium, dendritic cells, and neural cells. Both ICAM-1 and
VCAM-1 aremembers of the immunoglobulin gene superfamily. P-
, E-, and L-selectin belong to the selectin family of adhesion
molecules; E-selectin is expressed only on activated endothelium;
P-selectin is a membrane molecule platelet granule; L-selectin is
constitutively expressed on the surface of leukocytes.16–18
To our knowledge, this study is the ﬁrst tomeasure serum levels
of adhesion molecules, VEGF, and MIF in patients with CCHF and
suggests an association with disease severity. However, several
studies have been carried out for other hemorrhagic fevers,
particularly dengue virus infection. Combining data from previous
studies, only sVCAM-1 has been shown to be signiﬁcantly elevated
in patients with severe dengue virus infection; sICAM-1, sE-
selectin, sP-selectin, and sL-selectin levels have not been shown to
be signiﬁcantly elevated.18–20 These observations suggest that
sVCAM-1 could be a useful indicator for severity of infection. Our
ﬁndings are similar. We detected signiﬁcantly higher serum levels
of sVCAM-1 in severe CCHF cases. Thus, elevation of serum sVCAM-
1 levels could indicate endothelial activation. We also found that
serum levels of sVCAM-1might be an indicator of prognosis aswell
as the disease severity in CCHF. At a cut-off of 125 ng/ml, sVCAM-1
had 100% sensitivity and 42.5% speciﬁcity for prediction of
mortality. The signiﬁcance of these ﬁndings is not known at this
time. Further studies are required to elucidate the causes of
endothelial activation and damage in the pathogenesis of CCHF
infection.
Among adhesion molecules expressed on vascular endotheli-
um, serum levels of sVCAM-1 and sL-selectin were signiﬁcantly
higher in patients than in controls. An interpretation of this result
is that the endothelial damage in CCHF occurs via an indirect route
by inﬂammation rather than via direct viral invasion. However,
serum levels of sICAM-1, sP-selectin, and sE-selectin were
signiﬁcantly lower in patients than in controls. This is interesting,
and results must be conﬁrmed by further studies. In some reports,
serum levels of sICAM-1 have been found to be signiﬁcantly higher
in patients with dengue hemorrhagic fever (DHF) than in healthy
individuals.21 Despite lower levels of sICAM-1 in the patients than
the controls, elevated levels of sICAM-1 were observed in severe
cases and non-survivors in this study. Similar results have been
found in DHF in some studies.18 This can be explained as a
transient increase in sICAM-1 levels in response to the effect of
inﬂammatory cells and mediators in the severe stages of the
disease.
VEGF can be produced by monocytes and endothelial cells. It
plays an important role in the regulation of angiogenesis and
vascular permeability.22 Because the main pathophysiological
feature of DHF is the sudden increase in vascular permeability and
plasma leakage, most studies have been performed in patients
with dengue virus infection. Results of these studies, however,
have been inconsistent. In one study, plasma VEGF levels in
patients with DHF were signiﬁcantly higher than the values from
dengue fever (DF) patients, and it was suggested that VEGF might
contribute to the pathogenesis of DHF as a factor increasing
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that serum and plasma levels of VEGF were signiﬁcantly lower in
patients with DHF than DF at the toxic stage.24 They also showed
that both serum and plasma VEGFwere signiﬁcantly higher during
the recovery stage than during the toxic stage. In another study,
Srikiatkhachorn et al. observed a rise in the free VEGF but not total
VEGF in the plasma of DHF patients, associated with a decline in
the soluble form of the VEGF receptor 2 (VEGFR2) at the time of
plasma leakage.25 They concluded that the activity of VEGF was
controlled by binding to VEGFR2. The results of our study are
similar to those of the study of Sathupan et al. We found
signiﬁcantly lower serum VEGF levels in severe and fatal cases. We
also demonstrated that serum levels of soluble VEGF might be a
prognostic factor for CCHF. At the cut-off of 125 ng/ml, VEGF had
100% sensitivity and 54.5% speciﬁcity for the prediction of
mortality. The signiﬁcance of these ﬁndings is not clear. Further
studies are needed for conﬁrmation.
MIF is a pleiotropic cytokine that plays an important role in the
modulation of inﬂammatory and immune responses.26 Serum
levels of MIF are increased in patients with systemic inﬂammatory
response syndrome, sepsis, and septic shock.27,28 MIF levels are
correlatedwith death caused by sepsis.28 Chen et al. suggested that
serum levels of MIF are signiﬁcantly increased in DF patients, and
that the serum levels of MIF are correlated with disease severity
and with a fatal outcome in DHF patients.29 Similarly, our results
demonstrated that the serum MIF levels were signiﬁcantly higher
in CCHF patients than in controls. However, no signiﬁcant
difference was detected in severe and fatal cases.
In conclusion, the results of this study indicate that vascular
endothelial damage in CCHF patients is probably indirect and may
be caused by inﬂammatory cell activation. In addition, it was
demonstrated that endothelial activation can affect the course of
the disease. However, we need further studies to come to general
conclusions about the value of these variables in determining
disease severity.
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